Figure 4.
Selective Killing of Tumorigenic hPSCs by a Novel Oncolytic Virus Strategy
Survivin-responsive m-CRAs (Surv.m-CRAs), whose replication is controlled by the survivin promoter upstream of the adenoviral early region 1A (E1A), are promising anticancer agents that effectively and specifically treat a variety of cancers. The m-CRA platform technology is also applicable to selective eradication of tumorigenic cells in hPSC populations. Pre-infection of hPSCs with Surv.m-CRA results in efficient viral replication and cytocidal potential in undifferentiated cells, but not in differentiated cells.